MHRA position on UK licensing route for microbiome-based medicines

In this blog, Moira Francois explores the MHRA’s position on the UK licensing route for microbiome-based medicinal products (MBMPs), highlighting key regulatory, CMC, and GMO considerations for developers navigating this emerging therapeutic area.